Swedish Orphan Biovitrum Yönetim

Yönetim kriter kontrolleri 4/4

Swedish Orphan Biovitrum CEO'su Guido Oelkers, May2017 tarihinde atandı, in görev süresi 7.42 yıldır. in toplam yıllık tazminatı SEK 48.88M olup, şirket hissesi ve opsiyonları dahil olmak üzere 25.1% maaş ve 74.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.12% ine doğrudan sahiptir ve bu hisseler € 12.78M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.8 yıl ve 3.9 yıldır.

Anahtar bilgiler

Guido Oelkers

İcra Kurulu Başkanı

SEK 48.9m

Toplam tazminat

CEO maaş yüzdesi	25.1%
CEO görev süresi	7.4yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	5.8yrs
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Guido Oelkers'un ücretlendirmesi Swedish Orphan Biovitrum'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	SEK 4b
Jun 30 2024	n/a	n/a	SEK 2b
Mar 31 2024	n/a	n/a	SEK 2b
Dec 31 2023	SEK 49m	SEK 12m	SEK 2b
Sep 30 2023	n/a	n/a	SEK 3b
Jun 30 2023	n/a	n/a	SEK 3b
Mar 31 2023	n/a	n/a	SEK 3b
Dec 31 2022	SEK 47m	SEK 11m	SEK 3b
Sep 30 2022	n/a	n/a	SEK 2b
Jun 30 2022	n/a	n/a	SEK 3b
Mar 31 2022	n/a	n/a	SEK 3b
Dec 31 2021	SEK 42m	SEK 10m	SEK 3b
Sep 30 2021	n/a	n/a	SEK 3b
Jun 30 2021	n/a	n/a	SEK 3b
Mar 31 2021	n/a	n/a	SEK 3b
Dec 31 2020	SEK 33m	SEK 10m	SEK 3b
Sep 30 2020	n/a	n/a	SEK 3b
Jun 30 2020	n/a	n/a	SEK 3b
Mar 31 2020	n/a	n/a	SEK 4b
Dec 31 2019	SEK 33m	SEK 10m	SEK 3b
Sep 30 2019	n/a	n/a	SEK 3b
Jun 30 2019	n/a	n/a	SEK 3b
Mar 31 2019	n/a	n/a	SEK 3b
Dec 31 2018	SEK 26m	SEK 9m	SEK 2b
Sep 30 2018	n/a	n/a	SEK 2b
Jun 30 2018	n/a	n/a	SEK 2b
Mar 31 2018	n/a	n/a	SEK 1b
Dec 31 2017	SEK 16m	SEK 5m	SEK 1b

Tazminat ve Piyasa: Guido 'ın toplam tazminatı ($USD 4.58M ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.06M ).

Tazminat ve Kazançlar: Guido 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Guido Oelkers (59 yo)

7.4yrs

Görev süresi

SEK 48,883,000

Tazminat

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Guido Oelkers	CEO & President	7.4yrs	SEK 48.88m	0.12% € 12.8m
Henrik Stenqvist	Chief Financial Officer	6.3yrs	Veri yok	0.016% € 1.7m
Torbjörn Hallberg	General Counsel & Head of Legal Affairs	5.8yrs	Veri yok	0.0089% € 912.4k
Daniel Rankin	Head of Strategy & Corporate Development	2.8yrs	Veri yok	0.0029% € 293.8k
Lena Bjurner	Head of Human Resources	1.8yrs	Veri yok	Veri yok
Armin Reininger	Senior Scientific & Medical Advisor	7.8yrs	Veri yok	0.0047% € 478.8k
Norbert Oppitz	Head of International	7yrs	Veri yok	0.012% € 1.2m
Sofiane Fahmy	Head of Europe	5.8yrs	Veri yok	0.0077% € 793.2k
Duane Barnes	Head of North America	3.8yrs	Veri yok	Veri yok
Mahmood Ladha	Head of Strategic Transformation Operations	no data	Veri yok	0.0018% € 187.0k
Christine Wesstrom	Head of Technical Operations	2.6yrs	Veri yok	0.0032% € 330.8k
Lydia Abad-Franch	Senior VP	1.8yrs	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim: B6E0 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hans Wigzell	Chairman of Scientific Advisory Board	23.8yrs	SEK 158.00k	Veri yok
Helena Saxon	Director	13.5yrs	SEK 828.00k	0.0067% € 684.3k
Anders Ullman	Director	1.4yrs	SEK 463.00k	0.0010% € 102.7k
Stephen O'Rahilly	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Ralf Pettersson	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Stefan Del Prato	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jonathan Sanders Arch	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Annette Clancy	Independent Chairman	10.4yrs	SEK 770.00k	0.00099% € 101.7k
Staffan Schuberg	Independent Director	4.4yrs	SEK 827.00k	0.0021% € 213.7k
Filippa Stenberg	Director	3.4yrs	SEK 673.00k	0.00017% € 17.5k
Katy Mazibuko	Employee Representative Director	1.8yrs	Veri yok	0.0013% € 130.5k
Christophe Bourdon	Independent Director	1.4yrs	SEK 433.00k	Veri yok

3.9yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: B6E0 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).

Swedish Orphan Biovitrum Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Recent updates

Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2024 Results on Mar 31, 2025

Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

Sobi Announces the Publication of Full Results from the Phase 3 XTEND- Kids Study in Thenew England Journal of Medicine Confirming the Safety and Efficacy Profile of Altuvoct

Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024

Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout

European Commission Grants Sobi® Marketing Authorisation for Altuvoct™ for Treatment of Haemophilia A

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş